Torrey Pines Law GroupFree Consultation
≡
  • About Us
    • About Our Firm
    • The Advantages of Hiring Our Firm
    • Experience
    • Recent Successes
    • Client Testimonials
    • Careers
    • Diversity, Equity & Inclusion
    • Locations
    • Boston
      • Boston Patent Attorneys
      • Boston FDA Regulatory Counsel
      • Boston Technology Transactions
    • Irvine
      • Irvine Patent Attorneys
      • Irvine FDA Regulatory Counsel
      • Irvine Technology Transactions
    • Los Angeles
      • Los Angeles Patent Attorneys
      • Los Angeles FDA Regulatory Counsel
      • Los Angeles Technology Transactions
    • San Diego
      • San Diego Patent Attorneys
      • San Diego FDA Regulatory Counsel
      • San Diego Technology Transactions
  • Professionals
  • Intellectual Property
    • Comprehensive IP Protection
    • Patent Preparation & Prosecution
    • ● Artificial Intelligence Patents
    • ● Biotechnology Patents
    • ● Chemistry Patents
    • ● Convergence Technology Patents
    • ● In Vitro Diagnostics Patents
    • ● Lasers & Optics Patents
    • ● Medical Device Patents
    • ● Pharmaceutical Patents
    • ● Pharmaceutical Lifecycle Management
    • ● Semiconductor Patents
    • ● Software Patents
    • ● Telecommunications Patents
    • ● Telemedicine Patents
    • National Phase Entry (PCT)
    • IP Litigation
    • IP Opinions & Counseling
  • Tech Transactions
    • International Technology Transactions
    • Corporate Strategy
    • Business Agreements
    • Transactional Due Diligence
    • Intellectual Property Agreements
    • Intellectual Property Due Diligence
    • Regulatory Agreements
    • Regulatory Due Diligence
  • FDA Regulatory
    • Global Strategic Counseling
    • Dossier Submissions
    • Quality Compliance (ISO)
    • CE Mark - MDR Services
    • Digital Health
    • Hatch-Waxman & Biosimilars
    • Labeling, Advertising & Promotion
    • Reimbursement & Health Economics
  • FAQ
  • Contact
background
Hide
 
Show
  • background
  • torrey-pines-broken-hill
  • torrey-pines-sunset

Enablement

How to Make and Use an Invention Without "Undue" Experimentation

A patent must do more than describe an invention. It must also teach, or enable, a person in the same field to make or use the invention without them having to engage in an “undue” amount of guesswork or experimentation. If a patent does not enable the full scope that it claims, it can become invalid.

Under 35 U.S.C. §112(a), based on the 1988 court ruling In re Wands, 858 F.2d 731, courts use the “Wands factors” to help determine whether the disclosure meets the enablement standard. These factors include:

  • The quantity of experimentation necessary
  • The amount of direction or guidance presented
  • The presence or absence of working examples
  • The nature of the invention
  • The state of the prior art
  • The relative skill of those in the art
  • The predictability or unpredictability of the art
  • The breadth of the claims

Whether a patent application is enabled is also dependent upon the subject matter of the invention. A line of cases related to "predictable" inventions suggests that a single example of making and using the claimed invention is sufficient for enabling a person to practice the scope of patent application without undue experimentation. In a second line of cases related to "unpredictable" inventions such as biotechnology, pharmaceutical, and to a lesser degree medical device inventions, courts have held that a range of examples is desired to meet the enablement requirement.

Thus, it is our practice at Torrey Pines Law Group to describe as many alternative embodiments of an unpredictable invention as possible. If a variety of homologous polynucleotide or polypeptide sequences are effective in the invention, we ask our clients to descbibe them in examples. Examples are likewise requested with respect to alternative vectors, cell lines, salts, indications, analogs, algorithms, and the like. This provides the best opportunity to fully enable a patent application and issued patent.

≡
  • Should I choose to patent an innovation, or protect it as a trade secret?
  • What is "patent eligibility" under US patent law?
  • What is "novelty" under US patent law?
  • What is "obviousness" under US patent law?
  • What is "enablement" under US patent law?
  • What is the "written description" requirement under US patent law?
  • What is a US "Utility" patent application?
  • What is a US "Design" patent application?

Chambers Spotlight California 2026 Torrey Pines Law Group BCG 2026 Best Law Firms    Clio Reisman Award Torrey Pines Law Group    COPYRIGHT © , TORREY PINES LAW GROUP, PC. ALL RIGHTS RESERVED. | LEGAL NOTICES | SITE MAP

Torrey Pines Law Group, PC serves technology innovators with protecting intellectual property, obtaining regulatory approvals and clearances, and making deals and closing technology transactions throughout the U.S., including in major technology hubs such as San Diego, San Francisco, Palo Alto, San Jose, Silicon Valley, Boston, Cambridge, Chicago, Minneapolis, Houston, Dallas, Atlanta, Denver, Seattle, Portland, Boulder, Orlando, the Research Triangle (Raleigh, Durham, and Chapel Hill), the Mid-Atlantic (New Jersey, New York, Philadelphia, Maryland, Virginia, and Washington, DC), Pittsburgh, Cleveland, Ann Arbor, and throughout Southern California in Los Angeles, Orange County, Irvine, Torrey Pines, Sorrento Valley, and La Jolla.

We have experience with international intellectual property, regulatory and transactional matters pending in Beijing, Shanghai, Shenzhen, and Guangzhou China; Tokyo, Japan; Berlin, Munich and Frankfurt Germany; Tel Aviv Israel; Mumbai, Bengaluru, and New Delhi India; London and Edinburgh United Kingdom; Vancouver, Toronto, Calgary and Montreal Canada; Dublin, Ireland; Cape Town, South Africa; Mexico City and Tijuana Mexico; Brussels, Belgium; Copenhagen, Denmark; Paris, France; Madrid and Barcelona Spain; Moscow, Russia; Santiago, Chile; Montevideo, Uruguay; Buenos Aires, Argentina; Sao Paulo and Rio de Janeiro Brazil; Seoul, South Korea; Taipei, Taiwan; Hong Kong; Hanoi, Vietnam; Bangkok, Thailand; Kuala Lumpur, Malaysia; Milan, Italy; Singapore; Sydney, Melbourne, Perth and Adelaide Australia; Auckland, New Zealand; Oslo, Norway; Stockholm, Sweden; Helsinki, Finland; Kiev, Ukraine; Budapest, Hungary; Vienna, Austria; Prague, Czechia; Geneva and Lausanne Switzerland; Bahrain; Doha, Qatar; Abu Dhabi and Dubai UAE; and Jeddah, Saudi Arabia.